CROS

Executive Summary

CROS is a Polish clinical research organization (CRO) founded in 2008, providing comprehensive clinical development services across oncology, cardiovascular, and infectious disease indications. The company supports trials from preclinical through Phase I-IV, including first-in-human studies, for both commercial and non-commercial sponsors. As a private, pre-clinical stage firm, CROS leverages Poland's cost-efficient clinical trial environment and growing expertise in East European trial sites. While specific financials and pipeline details are not publicly disclosed, the CRO sector benefits from increasing outsourcing by biopharma companies. CROS's competitive edge lies in its full-service capabilities and therapeutic breadth, positioning it for steady growth in the contract research market. However, lack of public milestones or recent news limits visibility into near-term performance.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new strategic partnership with a major biopharma company70% success
• Q4 2026Completion of a Phase I/II trial milestone in oncology60% success
• Q2 2027Expansion of laboratory or facility capabilities in Warsaw50% success